Search PubMed⌕ Search

PubMed · 9232363

Changing delivery methods for obstructive lung diseases.

Abstract

There are three types of modalities for production of aerosolized medications, but numerous specific devices using these techniques are available. The recognition that children and adults need to use optimal methods to derive maximum therapeutic benefit with minimal side effects has resulted in recent developments such as spacers for pressurized metered-dose inhalers and breath-actuated dry powder inhalers and nebulizers. These methods provide finer aerosols that can be readily inhaled and deposited in the lung with improved efficiency. Delivery systems designed specifically for particular formulations have generally been well studied, but there is a paucity of information from manufactures characterizing the drug aerosols available from their devices. Clinicians are guided by data from drug trials, but must also be furnished with details of the delivery systems to allow them to compare devices and make intelligent choices for their patients. The material presented in this review provides an evaluation of some of the systems currently available for treating asthma and other lung diseases as well as a discussion of devices planned for the future.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Dolovich. 1997. Changing delivery methods for obstructive lung diseases.. https://doi.org/10.1097/00063198-199705000-00001

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗